Literature DB >> 3134016

Evidence of a novel association of unsaturated fatty acids with Gc (vitamin D-binding protein).

M H Williams1, E L Van Alstyne, R M Galbraith.   

Abstract

The strong sequence homology described recently between Gc (Vitamin D-binding protein) and albumin, and the ability of the latter, to bind 2-p-toluidinylnaphthylene sulfonate (TNS) promoted similar binding studies with Gc. TNS bound to native Gc as demonstrated by fluorescence, but chloroform:methanol extraction of Gc and gas chromatography revealed that large amounts of unsaturated fatty acids - 16:1, 18:1, 18:2 and 20:4 were also associated with Gc. In addition, TNS fluorescence was abolished by delipidation of Gc, and restored upon subsequent reconstitution with fatty acid. Finally, 70-80% of [3H]-arachidonic acid added to whole serum bound to Gc. These results demonstrated that TNS fluorescence of the native molecule reflects associated lipid, and suggest a novel role for Gc as a reservoir for a circulating pool of unsaturated fatty acids.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3134016     DOI: 10.1016/s0006-291x(88)81330-5

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Binding of GC (VDBP) to membranes of human B lymphocytes following stripping of extant protein.

Authors:  M Petrini; A Allegrini; F Ambrogi; P Valentini; A Sabbatini; P Arnaud; R M Galbraith
Journal:  J Endocrinol Invest       Date:  1995-09       Impact factor: 4.256

2.  1,25-Dihydroxycholecalciferol inhibits the cochemotactic activity of Gc (vitamin D binding protein).

Authors:  M Petrini; A Azzarà; G Carulli; B Grassi; F Ambrogi; R M Galbraith
Journal:  J Endocrinol Invest       Date:  1991-05       Impact factor: 4.256

Review 3.  Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding.

Authors:  F Hervé; S Urien; E Albengres; J C Duché; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

4.  Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP).

Authors:  J Arnaud; J Constans
Journal:  Hum Genet       Date:  1993-09       Impact factor: 4.132

5.  Fatty acid-binding site environments of serum vitamin D-binding protein and albumin are different.

Authors:  Narasimha Swamy; Rahul Ray
Journal:  Bioorg Chem       Date:  2008-03-28       Impact factor: 5.275

6.  Neutrophil recruitment to the lung in both C5a- and CXCL1-induced alveolitis is impaired in vitamin D-binding protein-deficient mice.

Authors:  Glenda Trujillo; David M Habiel; Lingyin Ge; Mahalakshmi Ramadass; Nancy E Cooke; Richard R Kew
Journal:  J Immunol       Date:  2013-06-10       Impact factor: 5.422

7.  The DBP Phenotype Gc-1f/Gc-1f Is Associated with Reduced Risk of Cancer. The Tromsø Study.

Authors:  Rolf Jorde; Henrik Schirmer; Tom Wilsgaard; Ellisiv Bøgeberg Mathiesen; Inger Njølstad; Maja-Lisa Løchen; Ragnar Martin Joakimsen; Guri Grimnes
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

8.  A novel role for a major component of the vitamin D axis: vitamin D binding protein-derived macrophage activating factor induces human breast cancer cell apoptosis through stimulation of macrophages.

Authors:  Lynda Thyer; Emma Ward; Rodney Smith; Maria Giulia Fiore; Stefano Magherini; Jacopo J V Branca; Gabriele Morucci; Massimo Gulisano; Marco Ruggiero; Stefania Pacini
Journal:  Nutrients       Date:  2013-07-08       Impact factor: 5.717

Review 9.  Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside.

Authors:  Ehsan Saburi; Amin Saburi; Mostafa Ghanei
Journal:  Caspian J Intern Med       Date:  2017

Review 10.  Common variants of the vitamin D binding protein gene and adverse health outcomes.

Authors:  Suneil Malik; Lei Fu; David James Juras; Mohamed Karmali; Betty Y L Wong; Agnes Gozdzik; David E C Cole
Journal:  Crit Rev Clin Lab Sci       Date:  2013-02-22       Impact factor: 6.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.